<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883827</url>
  </required_header>
  <id_info>
    <org_study_id>VICC URO 2144</org_study_id>
    <nct_id>NCT04883827</nct_id>
  </id_info>
  <brief_title>Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer</brief_title>
  <official_title>Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess whether DNA released by kidney cancer into the blood stream and urine&#xD;
      of patients can be used to monitor tumor burden and tumor response to treatment in patients&#xD;
      receiving immunotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      - Evaluate tumor cell free (cf)DNA as a dynamic marker of response to immuno-oncology (IO)&#xD;
      therapy&#xD;
&#xD;
      Exploratory Objective:&#xD;
&#xD;
      - Collect data on somatic mutations in cfDNA to gain insight into the biology of&#xD;
      IO-responders and -non-responders&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2021</start_date>
  <completion_date type="Anticipated">February 2026</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate tumor cfDNA as a dynamic marker of response to IO therapy</measure>
    <time_frame>Up to about 2 years</time_frame>
    <description>Measure of changes in the amount of tumor DNA correlated with result of routine tumor imaging studies</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>RCC with clear cell component</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>20-40 mL of blood to extract cell free DNA</description>
    <arm_group_label>Healthy Volunteer</arm_group_label>
    <arm_group_label>RCC with clear cell component</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urine collection</intervention_name>
    <description>up to 15 mL of urine to extract cell free DNA</description>
    <arm_group_label>Healthy Volunteer</arm_group_label>
    <arm_group_label>RCC with clear cell component</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults (18 year or older) with Renal Cell Carcinoma with clear cell component and receiving&#xD;
        an IO-containing regimen or healthy volunteers (18 years or older)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Renal Cell Carcinoma with clear cell component&#xD;
&#xD;
          -  Stage IV&#xD;
&#xD;
          -  Receiving IO-containing regimen&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active cancer (exclusion criteria only for healthy patient cohort)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Haake, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Haake, MD</last_name>
    <phone>615-936-8422</phone>
    <email>scott.haake@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
    <phone>800-811-8480</phone>
    <email>cip@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tennessee Valley Health Care System</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Haake, MD</last_name>
      <phone>615-936-8422</phone>
      <email>scott.haake@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Scott Haake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Haake, MD</last_name>
      <phone>615-936-8422</phone>
      <email>scott.haake@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
      <phone>800-811-8480</phone>
      <email>cip@vumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Scott Haake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Jonasch, MD</last_name>
      <email>ejonasch@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Eric Jonasch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Scott Haake, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 11, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT04883827/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

